SOCS1 and myeloid sarcoma: 79]. These examples suggest the oral bioavailability of these drugs through recognition by the mucosal immune system. Also, CPP for SOCS1-KIR given i.p. was shown to cross blood-brain barrier to protect against severe form of remitting/relapsing experimental allergic encephalomyelitis (EAE), the mouse model of multiple sclerosis (MS) [62].